BioXcel Therapeutics Announces BXCL501 Met the Primary and All Secondary Endpoints in the TRANQUILITY Phase 1b/2 Study for the Acute Treatment of Agitation in Dementia, including Alzheimer’s Disease

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

David Linetsky
Point-of-Care Marketing

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs

Bud Bilanich
Success Coach

Brenda Snow
Authentic Patient Voice

Matthew Durham
Omnidynamic Marketing

Pat Purcell
Meeting Engagement

Joey Cohen
Medication Adherence

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access